TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00860080
Drug: PXL01
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PXL01 is a synthetic peptide sequentially derived from human lactoferrin. The substance is formulated in a viscous solution of sodium hyaluronate. 10, 20, and 40 mg PXL01 will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.
Study: NCT02775292
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03959527
Drug: zoliflodacin
Normalized name: Zoliflodacin
DrugBank: Zoliflodacin (DB12817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: 3g, oral administration
Study: NCT03959527
Drug: ceftriaxone
Normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose: 500mg, Intra-Muscular (IM) administration
Study: NCT00217581
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Must be administered 2nd after Bevacizumab and followed by Oxaliplatin.70 mg/m(2), IV over 60 minutes, day 1 of each cycle;
Study: NCT00217581
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Must be administered 3rd after Bevacizumab and Docetaxel. 75 mg/m(2), IV over 120 minutes, Day 1 of each cycle.
Study: NCT00700024
Drug: Testim
Normalized name: Testim
DrugBank: Testosterone (DB00624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/dose7day
Study: NCT00734461
Drug: oxycodone and naltrexone
Normalized name: oxycodone and naltrexone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tablets containing 20 mg or 40 mg oxycodone~/ tablets containing 20 mg or 40 mg oxycodone combined w/0.001 mg or 0.0001 mg naltrexone
Study: NCT00428428
Drug: Isoproterenol
Normalized name: Isoproterenol
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ISO 0.1 microgram/ml, 8 ml/min irrigation compared to saline irrigation
Study: NCT00070564
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00926341
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tab. Pioglitazone-30 mg/day, oral, 24 weeks
Study: NCT00926341
Drug: Telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tab. Telmisartan- 40 mg/day, oral, 24 weeks
Study: NCT00460239
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intramuscular, doses (8, 16, 32, 48, 60 mg) are blind; administered up to 1-2 times per week.
Study: NCT00460239
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular; up to 1-2 times per week; doses (15, 30 mg) double blind
Study: NCT01996150
Drug: bleach bath (sodium hypochlorite)
Normalized name: beach strawberry extract
DrugBank: Strawberry (DB10571)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take diluted bleach bath (0.005% Sodium Hypochlorite) for 5-10 minutes twice a week for 12 weeks.
Study: NCT00032500
Drug: Echinacea
Normalized name: Echinacea
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00412789
Drug: Patupilone
Normalized name: Patupilone
DrugBank: Patupilone (DB03010)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00411723
Drug: RTL1000 (recombinant T cell receptor ligand)
Normalized name: RTL1000
DrugBank: RTL-1000 (DB17946)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: IV infusion. Dosage: Single dose @ 2, 6, 20, 60, 100 or 200mg. Duration: 1 - 2 hours.
Study: NCT04252885
Drug: Lopinavir and Ritonavir Tablets
Normalized name: Lopinavir and Ritonavir Tablets
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As indicated in arm/group descriptions
Study: NCT04252885
Drug: Arbidol
DrugBank: Umifenovir (DB13609)
Approvals — FDA: no, EMA: no, PMDA: no
Description: As indicated in arm/group descriptions
Study: NCT02170857
Drug: Hyaluronic Acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This material will be used in conjunction with the ordinary surgical procedure
Study: NCT00533221
Drug: somatotropin
Normalized name: Somatotropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0,015 mg/kg/d as one dose s.c. in the evening over one week followed by a 11 week period with 0,03 mg/kg/d s.c. as one dose in the evening
Study: NCT00608218
Drug: Ciclesonide
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is an observational study. Therefore, the physician decides about dosage according to individual needs.
Study: NCT00003115
Drug: hydromorphone hydrochloride
Normalized name: Hydromorphone Hydrochloride
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00770913
Drug: E3810
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg taken orally, once a day for 8 weeks.
Study: NCT00770913
Drug: E3810
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg, taken orally, twice a day for 8 weeks.
Study: NCT00770913
Drug: E3810
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg taken orally, twice a day for 8 weeks.
Study: NCT01472445
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02360280
Drug: ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sedative
Study: NCT02360280
Drug: midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: sedative
Study: NCT03130933
Drug: Amoxicillin 500 Mg
Normalized name: amoxicillin 500 MG
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The tested subgroups received a prophylactic single dose of 4 x 500 Mg Amoxicillin one hour prior the lower third molar surgery.
Study: NCT02583022
Drug: PAC-14028 cream 1.0%
DrugBank: PAC-14028 (DB12428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application
Study: NCT02583022
Drug: PAC-14028 cream vehicle
Normalized name: PAC-14028
DrugBank: PAC-14028 (DB12428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application
Study: NCT02654158
Drug: Low-dose of Fuganlin Oral Liquid
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: less than 1 years old: 5mL each time and three times a day~1\~3 years old: 10mL each time and three times a day~4\~6 years old: 10mL each time and four times a day~7\~12 years old: 10mL each time and five times a day
Study: NCT03011177
Drug: Teneligliptin
Normalized name: teneligliptin
DrugBank: Teneligliptin (DB11950)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: teneligliptin 20mg qd
Study: NCT03011177
Drug: Linagliptin
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: linagliptin 5mg qd
Study: NCT00098007
Drug: Everolimus (Certican)
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00650338
Drug: 0.005% latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical ocular application
Study: NCT04245618
Drug: neoadjuvant chemotherapy ( cisplatin - gemcitabine)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy before TURBT
Study: NCT00271219
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: daily oral dosing 20-140 mg
Study: NCT00271219
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sl daily 2-32 mg
Study: NCT02439788
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m2/day x 3 days; for patients \<12 kg the dose is 1 mg/kg/day x 3 days; Fludarabine will be given daily starting Day -4 prior to administration of GINAKIT cells
Study: NCT03848793
Drug: HS-20004
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment
Study: NCT00531947
Drug: Selegiline Transdermal System
Normalized name: Selegiline Transdermal System
DrugBank: Selegiline (DB01037)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study
Study: NCT00838383
Drug: sitaxsentan (Thelin)
DrugBank: Sitaxentan (DB06268)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: sitaxsentan (1.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.
Study: NCT00838383
Drug: sitaxsentan (Thelin)
DrugBank: Sitaxentan (DB06268)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Sitaxsentan (2.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.
Study: NCT00064077
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00064077
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00064077
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00064077
Drug: Topotecan Hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00064077
Drug: Vinorelbine Tartrate
Normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03828227
Drug: OPTIMOX-bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction Adapted FOLFOX7 (aFOLFOX7)-bevacizumab for 6 cycles (3 months)~* Bevacizumab: 5 mg/kg IV (day 1, every 2 weeks \[q2w\]),~* Folinic acid (FA): 400 mg/m² IV/2h (day 1, q2w),~* Oxaliplatin: 85 mg/m² IV/2h (day 1, q2w),~* 5-fluorouracil (5-FU) continuous infusion 2400 mg/m² IV/46h (day 1-2, q2w),~* No 5-FU bolus.~then Maintenance Adapted LV5FU2 (aLV5FU2)-bevacizumab (until progression or or unacceptable limiting toxicity)~* Bevacizumab: 5 mg/kg IV (day 1, q2w),~* FA: 400 mg/m² IV/2h (day 1, q2w),~* 5-FU continuous infusion 2400 mg/m² IV/46h (day 1-2, q2w)~* No 5-FU bolus
Study: NCT03828227
Drug: Capecitabine plus bevacizumab
Normalized name: Capecitabine
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Bevacizumab: 7.5 mg/kg intravenous infusion \[IV\] (day 1; q3w),~* Capecitabine: 1000 mg/m² orally twice a day (day 1 through day 14, q3w).
Study: NCT02400619
Drug: Botulinum Toxin Type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum toxin type A Botox
Study: NCT00168155
Drug: perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04008888
Drug: Melphalan Given IV
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: conditioning regimen: autologous ARM: Day -2 Melphalan 200 mg/m\^2/day IV over 30 minutes. allogeneic ARM: Day -4, Day -3 Melphalan 70 mg/m\^2/day IV over 30 minutes
Study: NCT04008888
Drug: Fludarabine Injection
Normalized name: fludarabine Injection
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: conditioning regimen:Days -6,-5,-4,-3 Fludarabine 30 mg/m\^2/day IV
Study: NCT04008888
Drug: PI and dexamethasone as maintenance therapy
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bortezomib and dexamethasone(VD),Ixazomib and dexamethasone(ID)
Study: NCT04008888
Drug: PI+IMids+Dexamethasone as Consolidated Chemotherapy
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral lenalidomide at the starting dose of 25mg on days 1-21 every 28 days or days 1-14 every 21 days. Dexamethasone at 20mg twice weekly on days 1,2,4,5,8,9,11\&12 of each 21-day.
Study: NCT03046953
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-PDL1 antibody
Study: NCT01199887
Drug: IW001
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IW001, 0.1 mg, 0.5 mg, 1.0 mg PO daily for 24 weeks.
Study: NCT02924233
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab is a humanized immunoglobulin G4 (IgG4) anti-PD-1 monoclonal antibody. Nivolumab will be administered via 60-minute infusion Q2W
Study: NCT00023738
Drug: dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00023738
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00023738
Drug: semaxanib
Normalized name: Semaxanib
DrugBank: Semaxanib (DB06436)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00200577
Drug: TIL + IL2
Normalized name: DAB(SUB 389)IL2
DrugBank: Denileukin diftitox (DB00004)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients are treated with 2 injections Of TIL (1st injection M1 and the second M2)The received concomitant IL2 at M1 and M2 on days Jo (injection TIL) to J5 and J8 to J12
Study: NCT00229749
Drug: AVI-4065 Injection
Normalized name: AVI-4065
DrugBank: AVI-4065 (DB05620)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01712139
Drug: Irbesartan and Hydrochlorothiazide
Normalized name: Irbesartan and Hydrochlorothiazide Tablets
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01712139
Drug: Avalide
Normalized name: Avalide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00656175
Drug: raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: raltegravir
Study: NCT02723448
Drug: aclarubicin
Normalized name: aclarubicin
DrugBank: Aclarubicin (DB11617)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclarubicin (3 mg/m²) will be administered intravenously through a central venous access device over 1 hour for four consecutive days per 28 day cycle. There is no maximum number of cycles.
Study: NCT00100347
Drug: PPI-2458
Normalized name: PPI-2458
DrugBank: PPI-2458 (DB05864)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02385110
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Group 1 and 2 Induction Phase: Alemtuzumab total dose of 1.0 mg/kg subcutaneously or by vein over 4 days (days 1-4) during the 8 week induction phase. Day 1 0.1 mg/kg, Day 2 0.3 mg/kg, Day 3 0.3 mg/kg, Day 4 0.3 mg/kg.~Group 1 Maintenance Phase: 0.2 mg/kg once every 4 weeks for 6 weeks.
Study: NCT02385110
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction Phase: 150 mg/m2 given by vein once a week for 8 weeks.~Maintenance Phase: Participants who have evidence of refractory disease or budding relapse during the maintenance phase may revert back to receiving Etoposide.
Study: NCT02385110
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction Phase: 10 mg/m2 for 1 week followed by Dexamethasone 5 mg/m2 for 2 weeks followed by Dexamethasone 2.5 mg/m2 for 2 weeks followed by Dexamethasone 1.25 mg/m2 for 2 weeks.~Maintenance Phase: 1.25 mg/m2 by mouth three times a week for 16 weeks.
Study: NCT02385110
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction Phase: Tocilizumab at 4 to 8 mg/kg by vein. Day 1 0.1 mg/kg,Day 2 0.3 mg/kg, Day 3 0.3 mg/kg, Day 4 0.3 mg/kg.
Study: NCT03934840
Drug: Cabazitaxel
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/m2 Q 21 days
Study: NCT03934840
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 4 Q21 Days x 6 cycles with ADT
Study: NCT03934840
Drug: Abiraterone
Normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg PO daily
Study: NCT03934840
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg PO daily on chemotherapy completion
Study: NCT04526665
Drug: Elafibranor 80mg
Normalized name: ELAFIBRANOR 80MG TAB
DrugBank: Elafibranor (DB05187)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elafibranor 80mg daily
Study: NCT01863615
Drug: Isotretinoin 40 mg
Normalized name: isotretinoin 40 MG
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Roaccutan 2 capsules of 20 mg; reference drug
Study: NCT01863615
Drug: Isotretinoin 40 mg
Normalized name: isotretinoin 40 MG
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oratane 2 capsules of 20 mg; test drug
Study: NCT02494895
Drug: Ticagrelor monotherapy
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor (Brilinta®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. Patients will be randomized to stop aspirin at 3 months after PCI.
Study: NCT02494895
Drug: Ticagrelor with Aspirin DAPT(dual antiplatelet treatment)
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor (Brilinta®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. Patients will be randomized to continue DAPT (aspirin+ticagrelor) up to 1 year.
Study: NCT02587195
Drug: Teriflunomide
Normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00275665
Drug: Valganciclovir
Normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02749227
Drug: Pasireotide LAR
Normalized name: pasireotide LAR 20 MG Injection
DrugBank: Pasireotide (DB06663)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pasireotide LAR (SIGNIFOR® LAR) is a somatostatin analog indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. It is a long acting release injectable suspension for intramuscular use.~The starting dose is Pasireotide LAR 40 mg/month intramuscular (IM), this will be increased to 60 mg/month at 6 months if a fall in POMC levels and/or tumor shrinkage are not attained.
Study: NCT02364583
Drug: Primaquine
Normalized name: Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Primaquine treatment given in a step-wise manner; (a) 0.5 mg/kg total dose daily for 14 days (n=40), (b) 1.0 mg/kg total dose daily for 7 days (n=40), (c) 1.0 mg/kg twice daily for 3.5 days (n=40)
Study: NCT01360788
Drug: Combination ipratropium/salbutamol or placebo (nebulization)
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The COPD patients were randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design. The bronchodilation produced by the medication was given in order to evaluate if bronchodilation was effective in increasing exercise tolerance during an endurance shuttle walking test in patients with GOLD stage I COPD.
Study: NCT01646840
Drug: PF-04958242 capsule
Normalized name: PF-04958242
DrugBank: PF-04958242 (DB11843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of PF-04958242 0.35 mg oral capsule
Study: NCT01646840
Drug: PF-04958242 oral solution
Normalized name: taurine
DrugBank: PF-04958242 (DB11843)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose of PF-04958242 0.35 mg oral solution
Study: NCT02136901
Drug: Intra-Articular Injections with Hyaluronic Acid (HA)
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.
Study: NCT02714205
Drug: transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will be randomized to transdermal nitroglycerin patch or placebo patch. Participants will wear a study medication patch daily, for 12 weeks.
Study: NCT01465230
Drug: Maintenance lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily maintenance treatment, oral lenalidomide
Study: NCT00905567
Drug: Topiramate 2 x 25 mg tablet
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02676739
Drug: Adderall XR
Normalized name: Adderall XR
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03770338
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20ug dosage daily injection, 1-month preoperative
Study: NCT02753816
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03017391
Drug: metoclopramide
Normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: metoclopramide 10 mg tablets 3x daily orally or suppositories 10 mg 3x daily rectally, use until toxicity
Study: NCT03017391
Drug: granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: granisetron patch 3.1mg/24 hours, use until toxicity
Study: NCT03017391
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexamethasone 8 mg, last step in both algorithms
Study: NCT03017391
Drug: Granisetron 2Mg Tablet
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: granisetron 2 mg loading dose
Study: NCT04346407
Drug: Dronabinol 2.5mg Cap
Normalized name: DRONABINOL 2.5MG CAP
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5mg of oral Dronabinol daily starting with pre-op cocktail and continued twice daily for three days after surgery
Study: NCT00381641
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO